Literature DB >> 5104099

The effect of chronic pyridostigmine administration on pyridostigmine-14C metabolism in myasthenia gravis.

P Kornfeld, R L Wolf, A J Samuels, K E Osserman.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1971        PMID: 5104099     DOI: 10.1212/wnl.21.5.550

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  3 in total

1.  A pharmacokinetic study of neostigmine in man using gas chromatography-mass spectrometry.

Authors:  S M Aquilonius; S A Eckernäs; P Hartvig; J Hultman; B Lindström; P O Osterman
Journal:  Eur J Clin Pharmacol       Date:  1979-06-12       Impact factor: 2.953

Review 2.  Clinical pharmacokinetics of cholinesterase inhibitors.

Authors:  S M Aquilonius; P Hartvig
Journal:  Clin Pharmacokinet       Date:  1986 May-Jun       Impact factor: 6.447

3.  Pharmacokinetics and oral bioavailability of pyridostigmine in man.

Authors:  S M Aquilonius; S A Eckernäs; P Hartvig; B Lindström; P O Osterman
Journal:  Eur J Clin Pharmacol       Date:  1980-11       Impact factor: 2.953

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.